News >

Pivotal Data in HER2+ Breast Cancer Transform Paradigm

Ellie Leick
Published: Wednesday, Nov 13, 2019

Erika P. Hamilton, MD, the director of the Breast Cancer Program at Sarah Cannon Research Institute

Erika P. Hamilton, MD
Research in HER2-positive breast cancer has led to a transition of traditional later-line therapies into earlier treatment settings to provide more options to patients with early-stage disease, explained Erika P. Hamilton, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication